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Guijun Yan,a Ni Zhu,a,b Shengdong Huang,b Bing Yi,a Xiying Shang,c Ming Chen,a Nadan Wang,a Guan-xin Zhang,b
Jennifer A. Talarico,c Douglas G. Tilley,c Erhe Gao,c Jianxin Suna,b
Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USAa; Department of Medicine, Changhai Hospital,
Second Military Medical University, Shanghai, Chinab; Center for Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania, USAc
The orphan nuclear receptor Nur77 plays critical roles in cardiovascular diseases, and its expression is markedly induced in the
heart after beta-adrenergic receptor (-AR) activation. However, the functional significance of Nur77 in -AR signaling in the
heart remains unclear. By using Northern blot, Western blot, and immunofluorescent staining assays, we showed that Nur77
expression was markedly upregulated in cardiomyocytes in response to multiple hypertrophic stimuli, including isoproterenol
(ISO), phenylephrine (PE), and endothelin-1 (ET-1). In a time- and dose-dependent manner, ISO increases Nur77 expression in
the nuclei of cardiomyocytes. Overexpression of Nur77 markedly inhibited ISO-induced cardiac hypertrophy by inducing nu-
clear translocation of Nur77 in cardiomyocytes. Furthermore, cardiac overexpression of Nur77 by intramyocardial injection of
Ad-Nur77 substantially inhibited cardiac hypertrophy and ameliorated cardiac dysfunction after chronic infusion of ISO in
mice. Mechanistically, we demonstrated that Nur77 functionally interacts with NFATc3 and GATA4 and inhibits their transcrip-
tional activities, which are critical for the development of cardiac hypertrophy. These results demonstrate for the first time that
Nur77 is a novel negative regulator for the -AR-induced cardiac hypertrophy through inhibiting the NFATc3 and GATA4 tran-
scriptional pathways. Targeting Nur77 may represent a potentially novel therapeutic strategy for preventing cardiac hypertro-
phy and heart failure.
Cardiac hypertrophy is an adaptive process in response to var-ious physiological or pathological stimuli associated with
neurohumoral activation, elevated wall stress, and changes in vol-
ume load (1). Although initially adaptive, persistent hypertrophy
induced by pathological conditions like myocardial infarction
and hypertension has detrimental consequences on the heart and
eventually progresses to heart failure, a major cause of death and
disability in the industrialized world (1). At cellular and molecular
levels, cardiac hypertrophy is characterized by increased myocyte
size, sarcomerogenesis, and reexpression of a set of fetal genes,
such as the atrial natriuretic factor, B-type natriuretic peptide, and
-myosin heavy chain genes, which are coordinately controlled by
a subset of hypertrophy-responsive transcription factors, includ-
ing myocyte enhancer factor 2 (MEF2), nuclear factor of activated
T cells (NFAT), and GATA4 (2, 3) (4). Depending on the up-
stream hypertrophic stimuli, these transcriptional regulators can
be directly phosphorylated or dephosphorylated by protein ki-
nases, such as mitogen-activated protein (MAP) kinase and pro-
tein kinases A and C, as well as the calcium-activated phosphatase
calcineurin, to facilitate hypertrophic gene expression (5–9). Dis-
ruption and/or attenuation of the activities of these transcription
factors could serve as a potential therapeutic approach in terms of
inhibiting the hypertrophic responses in the heart (10–12).
NR4A receptors are immediate early genes that are regulated
by various physiological stimuli, including growth factors, hor-
mones, and inflammatory signals, and are involved in a wide array
of important biological processes, including cell apoptosis, brain
development, glucose metabolism, and vascular remodeling (13).
The NR4A subfamily consists of 3 well-conserved members,
Nur77 (NR4A1), Nurr1 (NR4A2), and NOR-1 (NR4A3). Like
other nuclear receptors, NR4A receptors consist of an N-terminal
transactivation domain, a central 2-zinc-finger DNA-binding do-
main, and a C-terminal ligand-binding domain (13). So far, no
ligands have been identified for these receptors, and therefore they
are classified as orphan receptors. Recently, there has been much
attention paid to the function of these receptors in cardiovascular
system (14). In vascular smooth muscle cells, the expression of
Nur77 and NOR-1 was significantly induced by atherogenic stim-
uli, such as platelet-derived growth factor BB, epidermal growth
factor, and -thrombin, and overexpression of Nur77 has been
shown to inhibit cell proliferation and attenuate vascular injury-
induced neointimal formation in vivo (15, 16). NR4A nuclear re-
ceptors are also induced in vascular endothelial cells (ECs) by
several stimuli, such as hypoxia, tumor necrosis factor alpha
(TNF-), and vascular endothelial growth factor, and modulate
EC growth, survival, and angiogenesis (17, 18). Most importantly,
our recent study has implicated Nur77 as a potent negative regu-
lator for the proinflammatory response in ECs via a selective in-
hibition of NF-B activation (18). In cardiomyocytes, Nur77 ex-
pression can be induced by ischemia/reperfusion injury, and
translocation of Nur77 to the mitochondria mediates cardiomy-
ocyte apoptosis in response to oxidative stress (19). Interestingly,
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a recent report demonstrated that the expression of Nur77 in the
heart was rapidly induced in vivo following -adrenergic stimula-
tion (20, 21). However, at this time, the exact functional signifi-
cance of Nur77 in the heart remains unknown. Considering the
significant importance of -adrenergic signaling in cardiomyo-
cytes, we aimed to determine whether Nur77 is induced by -ad-
renergic stimulation in cardiomyocytes and whether Nur77 is in-
volved in -adrenergic cardiac hypertrophy and, if so, to
determine the molecular mechanism(s) involved.
MATERIALS AND METHODS
Primary culture of NRVMs. We obtained ventricles from 1-day-old
Sprague-Dawley rats and isolated cardiac myocytes through digestion
with trypsin-EDTA and type 2 collagenase as previously described (22).
The protocol was approved by the Institutional Animal Care and Use
Committee of the Thomas Jefferson University. Briefly, the tissues were
cut into small pieces and digested with 0.25% trypsin at 4°C overnight.
Collagenase (Worthington, Lakewood, NJ (1 mg/ml in Hanks balanced
salt solution [HBSS]) was used to further digest tissues in a shaking bath at
37°C for 20 min. The cell suspension was centrifuged at 1,000 rpm for 5
min and resuspended in Dulbecco modified Eagle medium (DMEM) with
1 g/liter glucose and 10% fetal bovine serum (FBS) (GIBCO). Cells were
cultured for 2 h to allow fibroblast cells to attach to the flask. Neonatal rat
ventricular myocytes (NRVMs) were collected from the supernatants and
cultured with DMEM containing 1 g/liter glucose plus 10% FBS and 1%
penicillin-streptomycin (GIBCO).
Northern blot analysis. Total RNA was isolated using TRIzol reagent
(Invitrogen) according to the instructions of the manufacturer. Total
RNA (20g per lane) was resolved on a 1% formaldehyde–agarose gel and
transferred onto a positively charged nylon membrane (Ambion) in
transfer buffer (1 mol/liter NaCl and 10 mmol/liter NaOH). The probes
were labeled with [-32P]dCTP (3,000 Ci/mmol; PerkinElmer) using a
random-primed DNA labeling kit (Ambion) and purified with NucAway
spin columns (Ambion). The blots were prehybridized and hybridized at
68°C in hybridization buffer (Sigma). After washing twice in 2 SSC (1
SSC is 0.15 M NaCl plus 0.015 M sodium citrate)– 0.1% SDS at 68°C for 20
min and once in 0.1 SSC– 0.1% SDS at 68°C for 30 min, the blots were
exposed to autoradiography film at 80°C using 2 intensifier screens.
Protein kinase A (PKA) inhibitor PKI (Santa Cruz), protein kinase C
(PKC) inhibitor GF109203X (GFX) (Tocris), phospholipase C (PLC) in-
hibitor U-73122 (Tocris), calcium channel blocker nifedipine (Tocris),
and beta-adrenergic receptor antagonist propranolol (Sigma) were used
to define the molecular signaling pathways mediating isoproterenol
(ISO)-induced Nur77 expression in cardiac cells.
Adenovirus construction. Adenoviruses harboring wild-type Flag-
tagged Nur77 (Ad-Nur77) and dominant negative Flag-tagged Nur77
lacking the transactivation domain (Ad-DN-Nur77) were made as previ-
ously described (18). The viruses were made and propagated in Ad293
cells and purified using CsCl2 banding.
Knockdown of Nur77 and luciferase assay. Cardiomyocytes were
seeded in 6-well plates, and knockdown of Nur77 was performed by using
Nur77 small interfering RNAs (siRNAs) with AllStars negative siRNAs
(Qiagen) as a control, as previously described (23). At 48 h after transfec-
tion, the cardiomyocytes were transfected with ANF-Luc reporter plasmid
(100 ng) using FuGene 6 transfection reagent. Approximately 48 h after
transfection, the myocytes were treated as indicated for an additional 24 h.
To determine the effect of Nur77 on the NFAT transcriptional activity,
myocytes were transduced with either Ad-lacZ or Ad-Nur77 (multiplicity
of infection [MOI], 30). At 24 h after transduction, myocytes were then
transduced with Ad-NFAT-Luc (MOI, 30) for another 24 h and then
stimulated with ISO (10mol/liter) or ET-1 (200 nmol/liter) for 24 h. Cell
lysates (20 l) were assayed for luciferase activity with a dual-luciferase
reporter assay system (Promega).
Measurements of cardiac hypertrophy. [3H]leucine uptake was mea-
sured as described previously (24). For staining of filamentous actin,
NRVMs were fixed in 3.7% formaldehyde, treated with 0.1% Triton
X-100 for 3 to 5 min, and then stained with Oregon Green 514 phalloidin
(Molecular Probes) at 5 units/ml for 20 min. Expression of atrial natri-
uretic factor (ANF), brain natriuretic peptide (BNP), and beta-myosin
heavy chain (-MHC) was determined by quantitative reverse transcrip-
tion-PCR (qRT-PCR) as described previously (11).
Immunofluorescence staining. For immunostaining Nur77, cardio-
myocytes were stimulated with 10 mol/liter ISO for 3 h, and then fixed
and sequentially incubated with anti–Nur77 polyclonal antibody (1:25
dilution; Santa Cruz) and fluorescein-5-isothiocyanate (FITC)-conju-
gated donkey anti-rabbit antibody (1:200 dilution, Invitrogen). For im-
munostaining of Flag-Nur77, cardiomyocytes were fixed and incubated
with Cy3-conjugated anti-Flag antibody (1:100 dilution, Sigma). Images
were visualized using an Olympus IX70 epifluorescence microscope.
Subcellular fractionation. Subcellular fractions were prepared by dif-
ferential centrifugation of cell homogenates as described previously (18).
Briefly, cells were homogenized manually in hypotonic buffer (10 mmol/
liter Tris-HCl [pH 7.5], 1 mmol/liter MgCl2, 1 mmol/liter EGTA, 1 mmol/
liter EDTA, 1 mmol/liter phenylmethylsulfonyl fluoride, 5g/ml leupep-
tin, and 5g/ml aprotinin). The nuclear fraction was obtained from low-
speed centrifugation (500  g), followed by 3 washes with phosphate-
buffered saline (PBS). For electrophoretic mobility shift assay (EMSA),
the nuclear fraction was dissolved in hypertonic buffer (20 mmol/liter
HEPES [pH 7.9], 420 mmol/liter NaCl, 1.5 mmol/liter MgCl2, 0.2 mmol/
liter EDTA, 25% glycerol, and the above-mentioned protease inhibitors).
After high-speed centrifugation at 12,800 g for 10 min, the supernatants
(nuclear extracts) were stored at80°C until use.
Coimmunoprecipitation. Neonatal rat cardiomyocytes (NRCMs)
were treated with 10 mol/liter ISO for 3 h. Cytoplasmic and nuclear
fractions were isolated. Coimmunoprecipitation of Nur77 and GATA4 or
NFATc3 was performed as described previously (25). To examine the
interaction of DN-Nur77 with GATA4 and NFATc3, NRCMs were trans-
duced with Ad-DN-Nur77 and then subjected to ISO stimulation for 3 h.
The following antibodies and beads were used for detection and immu-
noprecipitation: anti-GATA4 (Santa Cruz), anti-NFATc3 (Santa Cruz),
anti-Flag (Gene Script).
EMSA. The oligonucleotides corresponding to the consensus se-
quence of GATA4 (5=-CAC TTG ATA ACA GAA AGT GAT AAC TCT-
3=) was synthesized and labeled with IRDye 700 (IDT). Electrophoretic
mobility shift assay (EMSA) were performed with Odyssey IRDye 700
infrared dye-labeled double-stranded oligonucleotides coupled with the
EMSA buffer kit (Li-Cor Bioscience) according to the manufacturer’s
instructions. The specificity of the binding was examined using competi-
tion experiments and the gel supershift assay by adding GATA4 antibody
(Santa Cruz) prior to the addition of the fluorescently labeled probe.
Myocardial gene delivery.Myocardial gene delivery was performed as
previously described with some minor changes (26). Briefly, C57BL/6
mice (20 to 25 g) were anesthetized with 2% isoflurane inhalation and not
ventilated. A skin cut (1.2 cm) was made over the left chest, and the heart
was smoothly and gently “popped out” through a small hole made at the
fourth intercostal space. Twenty-five microliters of the gene of interest or
vehicle control was then injected directly into left ventricle (LV) free wall
with a syringe (Hamilton Co., Reno, NV) with a needle size of 30.5. After
gene delivery, the heart was immediately placed back into the intratho-
racic space, followed by manual evacuation of pneumothoraces and clo-
sure of muscle and the skin suture.
Implantation of Azlet mini-osmotic pumps. At 24 h after intramyo-
cardial injection with Ad-Nur77 or Ad-GFP, the mini-osmotic pump set
to dispense 0.5l/h for 14 days was filled with PBS or ISO (60 mg/kg/day)
and implanted subcutaneously in the back through a subscapular inci-
sion. Mice were monitored by echocardiogram prior to pump implanta-
tion and then weekly until the end of the 2-week period as described
previously (26).
Echocardiography.To measure global cardiac function, echocardiog-
raphy was performed with the VisualSonics VeVo 2100 imaging system in
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anesthetized animals (1.5% [vol/vol] isoflurane). The internal diameter of
the left ventricle was measured in the short-axis view from M-mode re-
cordings in end diastole and end systole as described previously (27).
Cardiomyocyte cross-sectional area. Axial cut tissue sections were
stained with Masson’s Trichrome and Alexa Fluor 594 conjugated with
wheat germ agglutinin. For each treatment group, 3 hearts were imaged
using a Nikon Eclipse Ti microscope with the 20 objective. Only myo-
cytes cut in the short axis with a visible nucleus were measured (minimum
of 200 cells per heart). Cell borders were planimetered manually by an
operator who was blinded to treatment group. Nikon NIS Elements soft-
ware was used to calculate 2-dimensional cross-sectional areas.
ChIP assay.Chromatin immunoprecipitation assay (ChIP assays were
performed as described previously (28). Briefly, NRCMs were cross-
linked for 10 min by directly adding formaldehyde (Sigma) to the culture
medium at a final concentration of 1%. The fixed cells were lysed with lysis
buffer (EZ ChIP; Upstate) and sonicated two times for 7 s with output 5
(Virsonic 60; Virtis) with a 2-min refractory period. For immunoprecipi-
tation, cell lysates were incubated with an antibody against GATA4 (5g;
Santa Cruz Biotechnology) or NFATc3 (5 g; Santa Cruz) overnight at
4°C. The immunoprecipitated and input DNAs were subjected to quan-
titative PCR with primers rANF (5=-GGTGTATGCCCCCTTCAAT-3=
and 5=-GCCAGGAAGCCAACATGATA-3=) and rBNP (5=-CCCTGTCA
TTTCCAATACGG-3= and 5=-CCAGCCCTTCTCATGGAGT-3=) to am-
plify rat promoter regions containing NFATc3- and GATA4-binding
sites.
Statistical analyses. Data are expressed as means standard errors of
the means (SEM). The statistical significance of differences was assessed
by Student t tests or analysis of variance (ANOVA), as appropriate; a P
value of	0.05 was considered statistically significant.
RESULTS
Upregulation of Nur77 by hypertrophic stimuli in NRVMs. To
investigate the role of NR4A nuclear receptors in cardiomyocyte
biology, we examined the expression of Nur77 in NRVMs in re-
sponse to a variety of hypertrophic stimuli. As shown in Fig. 1A,
except for angiotensin II, all tested stimuli, including fetal bovine
serum (FBS), phorbol 12-myristate 13-acetate (PMA), isoproter-
enol (ISO), phenylephrine (PE), and endothelin-1 (ET-1), mark-
edly upregulated the expression of Nur77 in NRVMs. Because the
critical importance of beta-adrenergic receptor (-AR) signaling
in cardiomyocyte hypertrophy, ISO was chosen to further inves-
tigate its effects on the expression of Nur77 in NRVMs. The time
course of Nur77 expression, when incubated with 10 mol/liter
ISO, showed a maximal induction of Nur77 expression at 1 h after
ISO stimulation (Fig. 1B). At a concentration of as low as 0.3
mol/liter, ISO induced Nur77 mRNA expression by approxi-
mately 3-fold. The maximal induction of ISO on Nur77 mRNA
expression was observed at the concentration of 1 mol/liter,
which increased Nur77 expression by approximately 20-fold (Fig.
1C). To further examine whether Nur77 expression is upregulated
in vivo by -AR stimulation, we collected the mouse hearts at 1 h,
3 h, 6 h, and 9 h after a single intraperitoneal injection of ISO (1
mg/kg). The mRNA expression of Nur77 in the heart was found to
be substantially induced within 1 to 3 h and reached a peak at 1 h,
with a maximal induction of approximately 25-fold (Fig. 1D).
To further determine the molecular signaling pathways in-
volved in ISO-induced Nur77 expression, NRVMs were pre-
treated with various kinase inhibitors 1 h prior to the ISO stimu-
lation. As shown in Fig. 1E, ISO-induced Nur77 expression was
completely inhibited by PKA inhibitor PKI, the calcium blocker,
and the -AR antagonist, suggesting that both PKA and intracel-
lular calcium pathways are involved in the expression of Nur77
induced by -AR stimulation in cardiomyocytes.
Protein expression of Nur77 was confirmed by both Western
blot and immunostaining analyses. As shown in Fig. 2A and B,
Nur77 protein was upregulated in NRVMs, in a time- and dose-
dependent fashion, by ISO treatment. Moreover, the immunore-
activity of Nur77 was increased predominantly in the nuclei of
cardiomyocytes (Fig. 2C). Western blot analysis also indicated
FIG 1 Induction of Nur77 expression by multiple hypertrophic stimuli. (A) NRVMs were treated with hypertrophic stimuli at the indicated concentrations for
1 h. Nur77 expression was determined by Northern blotting. (B) Time-dependent effect of ISO (10mol/liter) on Nur77 expression as determined by Northern
blotting. (C) Dose-dependent effect of ISO on Nur77 expression as determined by Northern blotting 1 h after ISO stimulation. (D) Adult mice were treated with
a single intraperitoneal injection of ISO (1 mg/kg), and their hearts were then harvested at the indicated time points for determining Nur77 expression by
qRT-PCR. *, P	 0.05 versus untreated control or time at 0 h. The data represent 3 independent experiments. (E) Myocytes were pretreated with vehicle, various
kinase inhibitors, or -AR antagonist for 1 h and then treated with ISO (10 mol/liter) for 1 h, and Nur77 expression was determined by Northern blotting.
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that ISO-induced Nur77 expression is localized primarily in the
nuclear fraction, while ET-1-induced Nur77 is predominantly in
cytoplasmic fraction (Fig. 2D). Chronic infusion of ISO into mice
resulted in a marked Nur77 expression at 24 h which then declined
to the baseline levels (Fig. 2E).
Nur77 attenuates ISO-induced cardiac hypertrophy. The in-
duction of Nur77 levels in response to hypertrophic stimuli
prompted us to speculate that Nur77 may play an important role
in regulating cardiac hypertrophy. Since ISO-induced Nur77 ex-
pression is transient, we hypothesized that persistent expression of
Nur77 may inhibit the development of cardiac hypertrophy. To
test this hypothesis, we examined the effect of Nur77 overexpres-
sion on ISO induced cardiac hypertrophy. As shown in Fig. 3A,
transduction of Ad-Nur77 (MOI 
 50) markedly inhibited sar-
comere organization induced by ISO. Furthermore, Nur77 over-
expression substantially inhibited both basal and ISO-stimulated
increases in cell size (Fig. 3B), protein synthesis (Fig. 3C), and
ANF mRNA transcription (Fig. 3D). Interestingly, overexpression
of dominant negative Nur77 (DN-Nur77), which is defective in its
transactivation domain, demonstrated effects similar to those for
wild-type Nur77 on ISO-induced cardiac hypertrophy, suggesting
that a nongenomic effect of Nur77 might be responsible for its
inhibitory effect on cardiac hypertrophy.
To test whether Nur77 has agonist-dependent specificity of
action on cardiomyocytes, we examined the effect of Nur77 on
PE- and ET-1-induced cardiac hypertrophy. Indeed, overexpres-
sion of both Nur77 and DN-Nur77 markedly inhibited the in-
creases in cardiac cell size, protein synthesis, and ANF expression
induced by PE (10 mol/liter) but not by ET-1 (100 nmol/liter)
(Fig. 3). These findings indicate that Nur77 functions as a nega-
tive-feedback regulator for both ISO- and PE-induced cardiac hy-
pertrophy but not for ET-1 induced hypertrophy.
It was previously reported that the subcellular localization of
Nur77 contributes to the diverse and sometimes even opposing
biological activities of Nur77 in cancer cell lines (29, 30). To de-
termine whether the subcellular localization of Nur77 accounts
for the specificity of the Nur77 effects on cardiac hypertrophy
induced by distinct agonists, we performed immunostaining to
examine the subcellular localization of Nur77 in cardiomyocytes
before and after ISO, PE, and ET-1 stimulation. Immunostaining
using Cy3-conjugated anti-Flag M2 antibody yielded a profound
perinuclear localization of Nur77 in cardiomyocytes infected with
Ad-Nur77 but not in Ad-LacZ-transduced cells (data not shown).
Intriguingly, both ISO and PE stimulation caused a rapid translo-
cation of both Nur77 and DN-Nur77 from the cytoplasm into the
nuclei of cardiomyocytes, whereas ET-1 had no effect on the
Nur77 translocation (Fig. 4A). Furthermore, both ISO- and PE-
induced Nur77 nuclear translocation was completely inhibited by
PKA inhibitor H89 but not by a PKC inhibitor, suggesting that the
PKA pathway may play a critical role in nuclear translocation of
Nur77 induced by ISO and PE (Fig. 4B). Together, the results
indicate that it is likely that the nuclear translocation of Nur77, as
induced by ISO and PE stimulation but not by ET-1, may contrib-
ute significantly to its inhibitory effect on cardiac hypertrophy.
Knockdown of Nur77 accelerates ISO-induced cardiac hy-
pertrophy. To further evaluate the functional role of endogenous
Nur77 in cardiac hypertrophy, we performed loss-of-function
studies. Transfection of myocytes with Nur77-specific siRNA
(siNur77) markedly inhibited both ISO and PE induced Nur77
expression in myocytes as determined by qRT-PCR (Fig. 5A) and
Western blotting (Fig. 5B). Furthermore, transfection of siNur77
significantly enhanced both ISO- and PE-induced increases in
protein synthesis, whereas the basal protein synthesis in unstimu-
lated cardiomyocytes was not affected (Fig. 5C). Likewise, knock-
down of Nur77 barely affected the basal ANF transcription but
significantly enhanced the ISO- and PE-induced ANF gene tran-
FIG 2 ISO increases Nur77 protein expression in NRVMs. (A) Myocytes were treated with ISO (10 mol/liter) for the indicated times. Nur77 expression was
determined by Western blotting (n
 3). *, P	 0.05 versus time zero. (B) Myocytes were treated with indicated concentrations of ISO for 3 h. Nur77 expression
was determined by Western blotting (n
 3). *, P	 0.05 versus ISO dose at time zero. (C) Myocytes were treated with ISO (10mol/liter) for 3 h and then fixed
and sequentially incubated with anti-Nur77 polyclonal antibody and FITC-conjugated donkey anti-rabbit antibody. Images were visualized using an epifluo-
rescence microscope. (D) Myocytes were treated with ISO (10mol/liter) or ET-1 (100 nmol/liter) for 3 h. Nuclear (Nucl) and cytoplasmic (Cyto) fractions were
isolated and subjected to Western blot analysis to determine expression of Nur77. (E) Mice were administered ISO with a mini-osmotic pump (60 mg/kg/day).
Hearts were harvested at the indicated time points, and Nur77 expression was determined by Western blotting (n
 3). *, P	 0.05 versus day 0.
Inhibition of Cardiac Hypertrophy by Nur77
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scription, as determined by ANF promoter-driven luciferase ac-
tivity (Fig. 5D). Taken together, these findings further suggest
that Nur77 is a negative regulator of ISO-induced cardiac hyper-
trophy.
Nur77 attenuates ISO-induced cardiac hypertrophy in vivo.
To further substantiate the in vivo functional significance of
Nur77 in cardiac hypertrophy, we explored whether cardiac over-
expression of Nur77 could inhibit cardiac hypertrophy in a mouse
model of hypertrophy induced by the chronic infusion of ISO (7).
To these ends, intramyocardial injection of Ad-Nur77 was applied
to induce the expression of Nur77 in the heart. At 2 weeks after
injection of Ad-Nur77, the expression of Nur77 was markedly
increased in Ad-Nur77-injected hearts compared with the Ad-
green fluorescent protein (Ad-GFP)-injected hearts (Fig. 6A), and
increased Nur77 expression was localized predominantly in the
nucleus as determined by immunoblotting on subcellular frac-
tionations (Fig. 6B) and immunofluorescent staining (Fig. 6C). A
single intramyocardial injection of Ad-Nur77 resulted in approx-
imately 50% of cardiac cells expressing Nur77 (Fig. 6C). Further-
more, myocardial overexpression of Nur77 markedly inhibited
ISO-induced cardiac hypertrophy, as demonstrated by heart
weight/body weight ratio (Fig. 7A and B), cross-sectional areas
(Fig. 7C and E) (Masson’s trichrome staining), and cross-sec-
tional diameter (Fig. 7D) (Alexa Fluor 594-conjugated wheat
germ agglutinin staining). In addition, ISO-induced upregulation
of hypertrophic markers, including ANF, BNP, and -MHC, was
attenuated in the hearts overexpressing Nur77 (Fig. 7F). Further-
more, we examined whether Nur77 overexpression can influence
FIG 4 ISO induces Nur77 translocation in cardiomyocytes. (A) Myocytes
were transduced with either Ad-Nur77 or Ad-DN-Nur77 (MOI, 50). At 24 h
after transduction, myocytes were cultured in serum-free medium for 24 h
prior to the stimulation with ISO (10mol/liter), PE (10mol/liter), or ET-1
(100 nmol/liter) for 3 h. Myocytes were then fixed and directly incubated with
Cy3-conjugated anti-Flag antibody. Images were visualized using epifluores-
cence microscope. (B) Myocytes were transduced with either Ad-Nur77 or
Ad-DN-Nur77 as indicated above and pretreated with H89 and GFX for 1 h
prior to stimulation with ISO (10mol/liter), PE (10mol/liter), or ET-1 (100
nmol/liter) for 3 h. Myocytes were then fixed and directly incubated with
Cy3-conjugated anti-Flag antibody.
FIG 3 Effect of Nur77 on ISO-induced cardiac hypertrophy. (A) Myocytes were transduced with either Ad-Nur77, Ad-DN-Nur77, or Ad-LacZ (MOI, 50) and
stimulated with ISO (10mol/liter), PE (10mol/liter), or ET-1 (100 nmol/liter) for 48 h. The cells were stained with Oregon Green 514-phalloidin to visualize
actin fibers. (B) The mean myocyte surface area (top) was obtained from 300 myocytes/well. (C) Cardiomyocytes cultured in 24-well plates were transduced with
adenoviruses as indicated and cultured in serum-free medium for 24 h prior to stimulation with ISO (10mol/liter), PE (10mol/liter), or ET-1 (100 nmol/liter)
for 24 h. [3H]leucine was added at 1 Ci per well, and incubation was continued for 6 h. The cells were washed and fixed with cold 5% trichloroacetic acid, and
the radioactivity incorporated into the trichloroacetic acid-precipitable material was determined. The data are means  standard errors (SE) from five inde-
pendent studies. (D) Cardiomyocytes were transduced with the indicated adenoviruses (MOI, 50). At 24 h after transduction, myocytes were cultured in
serum-free medium for 24 h prior to the stimulation with ISO (10mol/liter), PE (10mol/liter), or ET-1 (100 nmol/liter) for 48 h. The expression of ANF was
determined by Northern blotting.
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cardiac structure and function in vivo via echocardiography. In-
deed, chronic administration of ISO significantly increased LV
anterior wall thickness, which was significantly blunted when
Nur77 was overexpressed (Fig. 8A and B). Overexpression of
Nur77 also markedly attenuated the ISO-induced functional de-
compensation (Fig. 8C and D) but barely affected the ISO-in-
duced increase in heart rate (Fig. 8E) and apoptosis as determined
by terminal deoxynucleotidyltransferase-mediated dUTP-biotin
nick end labeling (TUNEL) staining (data not shown). Together,
these data suggest that upregulation of Nur77 in the heart inhibits
ISO-induced cardiac hypertrophy and cardiac dysfunction in the
animal model.
Nur77 inhibits transcriptional activities of NFATc3 and
GATA4 in NRVMs. DN-Nur77, which lacks the transcriptional
activation domain of Nur77, demonstrated as potent a antihyper-
trophic effect as wild-type Nur77, suggesting that the nongenomic
effect of Nur77, such as protein-protein interactions in the nu-
cleus, may be responsible for its antihypertrophic effects in cardi-
omyocytes. Furthermore, the aberrant activation of transcrip-
tional pathways, such as the calcineurin/NFAT and GATA4
pathways, has been reported to play critical roles in ISO-induced
cardiac hypertrophy (4, 10, 31). Therefore, to investigate the
mechanism(s) responsible for the inhibitory effects of Nur77 on
ISO-induced cardiac hypertrophy, we first examined whether
there is a functional interaction of Nur77 with NFATc3, which is a
key transcription factor for multiple cardiac hypertrophic signal-
ing in the nuclei of cardiomyocytes. To this end, we performed
coimmunoprecipitation with either anti-Nur77 or anti-NFATc3
antibody using lysates obtained from cardiomyocytes. As shown
in Fig. 9A, Nur77 coprecipitated with the anti-NFATc3 antibody
but not with the nonimmune control, indicating that the endog-
enous levels of Nur77 can specifically interact with NFATc3 in
cardiomyocytes. To determine whether the interaction of Nur77
with NFATc3 affects the transcriptional activity of NFATc3, we
transduced cardiomyocytes with adenovirus bearing an NFAT-
luciferase reporter gene. As shown in Fig. 9B, ISO stimulation
markedly increased the NFAT-luciferase activity in Ad-LacZ-
FIG 5 Knockdown of Nur77 accelerates ISO induced cardiac hypertrophy. (A) Myocytes were transfected with Nur77 siRNA (siNur77) or control siRNA
(siCTL). At 72 h after transduction, cells were cultured in serum-free medium for 24 h prior to stimulation with ISO (10 mol/liter) or PE (10 mol/liter) for
1 h. The expression of Nur77 was determined by qRT-PCR. The data represent 5 independent experiments. (B) Myocytes were transfected with siNur77) or
siCTL. At 72 h after transduction, Nur77 expression was determined by Western blotting after stimulation with ISO (10mol/liter) or PE (10mol/liter) for 3 h.
(C) Myocytes cultured in 24-well plates were transfected with siNur77 or siCTL. At 72 h after transduction, cells were cultured in serum-free medium for 24 h
prior to stimulation with ISO (10 mol/liter) or PE (10 mol/liter) for 24 h. Leucine incorporation was determined (n
 5). (D) Myocytes cultured in 24-well
plates were transfected with siNur77 or siCTL. At 48 h after transduction, myocytes were transfected with ANF-Luc and then stimulated with ISO (10mol/liter)
or PE (10 mol/liter) for 24 h. Luciferase assays were performed (n
 5).
FIG 6 Expression of Nur77 in the heart after intramyocardial injection of
Ad-Nur77. (A) At 2 weeks after intramyocardial injection of Ad-GFP or Ad-
Nur77, Nur77 expression was determined by Western blotting. (B) At 14 days
after chronic infusion of ISO, Nur77 expression in cytoplasmic and nuclear
fractions in mouse hearts injected with either Ad-GFP or Ad-Nur77 was de-
termined by Western blotting. (C) At 14 days after ISO infusion, Nur77 ex-
pression was determined in the heart by immunofluorescent staining using
anti-Flag antibody.
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transduced cardiomyocytes, which was inhibited in cardio-
myocytes overexpressing Nur77. In addition, the ISO-stimulated
binding of NFATc3 to the ANF promoter was significantly atten-
uated by Nur77 as determined by chromatin immunoprecipita-
tion (ChIP) assay (Fig. 9C). In contrast, Nur77 overexpression
had no effect on ET-1-induced NFAT-luciferase activity (Fig. 9B).
GATA4 has been previously reported to regulate cardiac hy-
pertrophy through a cooperative interaction with NFAT (31, 32).
Similarly, Nur77 specifically interacts with GATA4 in neonatal rat
cardiomyocytes as determined by coimmunoprecipitation (Fig.
10A). Similar to wild-type Nur77, DN-Nur77 also interacts with
both GATA4 and NFATc3 in ISO-stimulated cardiomyocytes
(Fig. 10B) but not in ET-1-stimulated cells (data not shown). To
determine whether Nur77 affects the GATA4-mediated transcrip-
tion pathway in cardiomyocytes, we performed EMSA with the
nuclear extracts obtained from cardiomyocytes transduced with
either Ad-lacZ or Ad-Nur77. As shown in Fig. 10C, in Ad-LacZ-
infected cells, ISO stimulation led to a formation of a strong sin-
gular DNA-protein complex containing GATA4, which was veri-
fied by both competition and supershift studies. This GATA4
DNA binding, however, was markedly attenuated in the nuclear
extracts from Nur77-overexpressing myocytes. Moreover, over-
expression of Nur77 markedly attenuated the ISO-stimulated
GATA4 binding to its consensus site in the BNP promoter as de-
termined by ChIP assay (Fig. 10D). Together, these data suggest
that Nur77 inhibits ISO-induced cardiac hypertrophy, at least in
part, through the inhibition of the NFAT and GATA4 transcrip-
tional pathways.
DISCUSSION
In this study, we have found that Nur77, an orphan nuclear recep-
tor, has antihypertrophic properties in cardiomyocytes. We dem-
onstrated that Nur77 expression is markedly upregulated in re-
sponse to multiple hypertrophic stimuli, such as ISO and PE, and
acts as a potent inhibitor for both ISO- and PE-induced hypertro-
phy. Our results show that ISO-induced expression of Nur77 is
transient and that chronic stimulation of cardiac cells with ISO led
to a decline of Nur77 expression to the baseline levels in mouse
heart, which may inactivate the negative-feedback loop of Nur77
and lead to the development of cardiac hypertrophy. Therefore,
we speculated that persistent expression of Nur77 would be a ther-
apeutic strategy to block the ISO-induced cardiac hypertrophy.
Consistent with this hypothesis, our results demonstrated that
intramyocardial injection of Ad-Nur77 significantly ameliorated
ISO-induced cardiac hypertrophy and preserved the cardiac dys-
function in the animal model after chronic infusion of ISO for 2
weeks. However, Nur77 overexpression barely affected the base-
line expression of hypertrophic marker genes, which is different
FIG 7 Cardiac Nur77 overexpression reduces ISO-induced myocardial hypertrophy. (A) Representative whole-heart picture taken at the end of a 2-week ISO
pump infusion in Ad-GFP-PBS (a), Ad-GFP-ISO (b), Ad-Nur77-PBS (c), and Ad-Nur77-ISO (d) groups. (B) Ratio of heart weight (HW) to body weight (BW),
*, P	 0.05 versus Ad-GFP-PBS; #, P	 0.05 versus Ad-GFP-ISO. (C) Representative heart tissue sections stained with Masson’s trichrome. (D) Representative
heart tissue sections stained with Alexa Fluor 594-conjugated wheat germ agglutinin. (E) Summary of cross-sectional area from panel C. *, P 	 0.05 versus
Ad-GFP-PBS group; #, P	 0.05 versus Ad-GFP-ISO (n
 5 for each group). (F) Expression of ANF, BNP, and -MHC was examined by qRT-PCR. *, P	 0.05
versus Ad-GFP-PBS group; #, P	 0.05 versus Ad-GFP-ISO (n
 5 for each group).
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from what we observed in neonatal cardiomyocytes. Intriguingly,
DN-Nur77, which is defective in its transactivation domain, also
inhibited ISO-induced cardiac hypertrophy to the same extent as
the wild-type Nur77 in cardiomyocytes, suggesting an involve-
ment of the nongenomic effect of Nur77 in its antihypertrophic
effect. Indeed, we found that in the nuclei of cardiomyocytes,
Nur77 functionally interacts with at least two important prohy-
pertrophic transcription factors, NFATc3 and GATA4, and sup-
presses their transcriptional activities. Therefore, we provide, for
the first time, compelling evidence suggesting that the orphan
nuclear receptor Nur77 functions as a novel negative inhibitor for
ISO-induced cardiac hypertrophy, at least in part, through inhib-
iting the NFAT and GATA4 transcriptional pathways in cardio-
myocytes.
Recently, the cardiovascular function of the NR4A receptor has
received significant attention (14). Accumulating evidence sug-
gests that NR4A receptors play essential roles in the development
of atherosclerosis, restenosis, and angiogenesis (17, 18, 33). How-
ever, the functional role of the NR4A receptor in cardiomyocyte
biology remains largely obscured, although several studies suggest
that the NR4A receptors are highly expressed in the heart and that
their expression is regulated by several external pathological stim-
uli, such as oxidative stress, pressure overload, and -AR activa-
tion (19, 20, 34). In the present study, we sought to examine the
role of Nur77 in cardiac hypertrophy and found that the expres-
sion of Nur77 is substantially increased in response to a wide range
of hypertrophic stimuli. Furthermore, we demonstrated that
stimulation of cardiomyocytes with the -AR agonist ISO caused
a rapid and robust induction of Nur77, mainly through the PKA-
and intracellular calcium-dependent signaling pathways. Pre-
dominant nuclear localization of the induced Nur77 in cardiac
cells prompted us to postulate that Nur77 may be a critical regu-
lator of the -AR-induced molecular signaling pathway in the
nuclei of cardiomyocytes. Indeed, the activation of transcriptional
factors in the nuclei of cardiomyocytes has been well established to
contribute significantly to the development of cardiac hypertro-
phy. For instance, the activation of the transcriptional factor
NFAT pathway has been demonstrated in a majority of models of
pathological cardiac hypertrophy and plays an essential role in
mediating -AR hypertrophy and heart failure (32). Under basal
and unstimulated conditions, NFAT is phosphorylated and re-
sides in the cytoplasm. Stimulation of cardiac cells with hypertro-
phic stimuli such as ISO and PE can rapidly cause the activation of
the calcium-dependent phosphatase calcineurin (PP2B), which in
turn dephosphorylates NFAT, thus facilitating its nuclear translo-
cation and transcriptional activation of target genes essential for
cardiac hypertrophy (10, 35). In the current study, our data clearly
indicated that Nur77 associates with NFATc3 after ISO stimula-
tion, therefore suppressing its transcriptional activity, which is
mainly responsible for the inhibitory effects of Nur77 on the
-AR-induced cardiomyocyte hypertrophy.
Our data also indicate that Nur77 can inhibit the transcrip-
tional activity of GATA4, another critical transcriptional factor
involved in cardiac hypertrophy. In cardiomyocytes, through a
cooperative interaction with other transcription factors such as
NFAT-3c and MEF-2, GATA4 has been shown to increase cell size,
protein synthesis, and expression of prohypertrophic genes (31,
36). Direct interaction of GATA4 with NFAT has been shown to
synergistically regulate the hypertrophic gene expression in the
heart (31, 32). In addition, the transcriptional activity of GATA4 is
regulated by posttranslational modifications, such as phosphory-
lation, acetylation, and methylation (4, 37, 38). Both MAP kinase
and phosphatidylinositol (PI) 3-kinase/Akt/glycogen synthase ki-
nase (GSK) pathways can phosphorylate GATA4 and regulate its
transcriptional activity in the heart (4, 39). p300, a transcriptional
coactivator, also directly interacts with GATA4 to synergistically
activate the ANF and -MHC promoters during myocardial hy-
pertrophy (40, 41). In the present study, we demonstrated that
Nur77 potently inhibits the GATA4 DNA binding and transcrip-
tional activity through an inhibitory interaction with GATA4.
FIG 8 Cardiac function was measured by echocardiography at 2 weeks after ISO pump infusion. (A) Representative echocardiograph from the various groups.
(B and C) The left ventricle systolic anterior wall depth (LVAWDs) (B) and the LV internal diameters of diastole (LVIDd) (C) were measured at the view of the
short axis from M mode. (D and E) LV ejection fraction (D) and heart rate (HR) (E) were calculated using VisualSonic analysis software (n
 5 animals/group).
*, P	 0.05 versus Ad-GFP-ISO; #, P	 0.05 versus Ad-GFP-PBS.
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However, whether Nur77 inhibits the GATA4 transcriptional
pathway through its action on the posttranslational modification
of GATA4 warrants further investigation.
In addition to inhibiting ISO-induced cardiac hypertrophy,
Nur77 also inhibits PE-induced hypertrophy, but it has no effect
on ET-1-induced cardiac hypertrophy. The differential effects of
Nur77 on cardiac hypertrophy induced by different stimuli seem
largely due to the intracellular localization of Nur77 in cardiomy-
ocytes. In response to ISO and PE stimulation, Nur77 is rapidly
translocated to the nuclei of cardiomyocytes, whereas ET-1 stim-
ulation did not induce the nuclear translocation of Nur77, al-
though ET-1 has been shown to induce the Nur77 expression to a
similar extent as both ISO and PE did in cardiomyocytes. These
results indicate a critical role of the nuclear localization of Nur77
in eliciting its antihypertrophic effects. Recently, Nur77 has been
shown to be induced by 500 nmol/liter angiotensin II in NRVMs
and to promote angiotensin II-induced cardiac hypertrophy
through a cytoplasmic interaction with the TSC1/TSC2 complex
(42). In our study, Nur77 expression was not significantly induced
by angiotensin II at a concentration of 100 nmol/liter, which was
much lower than the 500 nmol/liter used in the above-mentioned
study (42). Indeed, multiple lines of evidence suggest that depend-
ing on the stimuli and its cellular localization, Nur77 can exert
different or even opposite effects (29, 30). For instance, in re-
sponse to certain apoptosis-inducing agents, Nur77 expression is
induced in some cancer cells, and it subsequently translocates
from the nucleus to mitochondria, where it causes the conforma-
tional change of Bcl-2 to promote apoptosis (30). While in the
nucleus, Nur77 can function as a transcription factor by binding
to its DNA response elements of target genes to promote cancer
cell growth and survival (43, 44). Recently, Nur77 has been shown
to function as a positive regulator of skeletal muscle growth in
mice by transcriptional induction of insulin-like growth factor 1
(IGF1) as well as downregulation of growth-inhibitory genes (45).
Our data suggest that such a genomic action of Nur77 is not likely
involved in its antihypertrophic effect in cardiomyocytes, since
DN-Nur77, which lacks the functional N-terminal AF-1 domain
of Nur77, exerts the same antihypertrophic effects as wild-type
Nur77, suggesting that the nongenomic action of Nur77, such as
protein-protein interactions, may contribute to its antihypertro-
phic effect. At this point, the molecular mechanism mediating the
translocation of Nur77 in cardiomyocytes remains elusive, but it
may be dependent on the phosphorylation status of Nur77, as has
been previously shown in some noncardiac cells lines. Several ki-
nases, including PKA, PKC, Jun N-terminal protein kinase (JNK),
p90 ribosomal S6 kinase (RSK), and Akt, have been reported to
phosphorylate Nur77 in various in vitro and in vivo experiments
(43, 46, 47). Phosphorylation of Nur77 by PKC, JNK, and RSK has
been reported to target Nur77 to the mitochondria and induce cell
apoptosis in T cells (29, 48) (48), whereas the Akt-mediated phos-
phorylation inhibits this process (43). In cardiomyocytes, our pre-
liminary data indicate that inhibition of PKA but not PKC com-
pletely abolished the ISO- and PE-induced nuclear translocation,
highlighting the importance of the PKA pathway in the transloca-
tion of Nur77 from the cytoplasm to the nuclei in cardiomyocytes.
Indeed, PKA has been shown to phosphorylate Nur77 in an in
vitro experiment (49); whether this phosphorylation mediates
Nur77 translocation, however, is unknown. Thus, it would be
FIG 9 Functional interaction of Nur77 with NFATc3. (A) Myocytes were treated with ISO (10 mol/liter) for 3 h. The nuclear fraction of cardiomyocytes was
isolated and then subjected to immunoprecipitation with either normal IgG, anti-NFATc3, or anti-Nur77 antibody. Immunocomplexes were separated by 10%
SDS-PAGE and immunoblotted with either anti-Nur77 or NFATc3 antibody. (B) Myocytes were transduced with either Ad-LacZ or Ad-Nur77 (MOI, 30). At 24
h after transduction, myocytes were then transduced with Ad-NFAT-Luc (MOI, 30). At 24 h after transduction, myocytes were starved and stimulated with ISO
(10mol/liter) or ET-1 (200 nmol/liter) for 24 h, and luciferase assays were performed (n
 5). *, P	 0.05 versus Ad-LacZ with Veh or Ad-Nur77 with ISO. (C)
Nur77 inhibits the binding activity of NFATc3 to the ANF promoter. NRCMs were infected with Ad-Nur77 or Ad-LacZ for 48 h and then treated with vehicle or
10 mol/liter ISO for 3 h. PCR analysis of sheared DNA from control and adenovirus-infected cells before immunoprecipitation (input) and after chromatin
immunoprecipitation (ChIP) with antibody directed against NFATc3 and quantitative analysis of ChIP results from three independent experiments are shown.
*, P	 0.05 versus Ad-LacZ without ISO; #, P	 0.05 versus Ad-LacZ with ISO.
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interesting to investigate where Nur77 is a substrate of PKA and
whether the PKA-mediated Nur77 phosphorylation accounts for
its nuclear translocation in cardiomyocytes.
Overall, the data reported here provide evidence that the or-
phan nuclear receptor Nur77 is a novel negative-feedback regula-
tor of cardiac hypertrophy in response to -AR stimulation via
inhibiting both NFAT and GATA4 transcriptional pathways.
Chronic stimulation of the -AR has been shown to contribute
significantly to the development of progressive cardiac dysfunc-
tion and cardiac remodeling in patients (50). Understanding the
molecular mechanism, particularly identifying the negative regu-
lators of -AR signaling in cardiomyocytes, will be of critical im-
portance for a better treatment of patients with heart failure. In
this regard, identification of Nur77 as a negative regulator of the
-AR signaling in cardiomyocytes may represent a potentially
novel therapeutic strategy for preventing cardiac hypertrophy and
heart failure.
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